Xeris Biopharma Holdings (XERS) Change in Receivables (2020 - 2026)

Xeris Biopharma Holdings' Change in Receivables history runs 7 years deep, the most recent figure standing at $5.2 million for Q1 2026.

• Quarterly Change in Receivables fell 11.33% year-over-year to $5.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.0 million (up 11.77% YoY) and the FY2025 annual result came in at $10.6 million, up 773.15% from the prior year.
• Change in Receivables was $5.2 million for Q1 2026 at Xeris Biopharma Holdings, up from -$2.7 million in the prior quarter.
• Across five years, Change in Receivables topped out at $15.7 million in Q3 2023 and bottomed at -$6.8 million in Q4 2023.
• A 5-year average of $2.3 million and a median of $1.8 million in 2022 frame the typical range for Change in Receivables.
• Peak annual rise in Change in Receivables reached 891.5% in 2024, while the deepest fall reached 6043.33% in 2024.
• Xeris Biopharma Holdings' Change in Receivables stood at $3.3 million in 2022, then tumbled by 304.38% to -$6.8 million in 2023, then soared by 89.32% to -$723000.0 in 2024, then tumbled by 273.58% to -$2.7 million in 2025, then jumped by 294.19% to $5.2 million in 2026.
• Business Quant data shows XERS's Change in Receivables at $5.2 million in Q1 2026, -$2.7 million in Q4 2025, and $703000.0 in Q3 2025.